A.

      ELONOVA is a biotechnology company developing next-generation mRNA therapeutics. We focus on innovative mRNA chemistry and platform technologies to enhance protein expression, durability, and therapeutic efficacy.

      A.

      MSCap™ is ELONOVA’s proprietary mRNA capping technology designed to significantly enhance cap-dependent translation and improve overall mRNA performance.

      A.

      MSCap™ is based on novel chemically engineered cap structures that provide superior translation efficiency and functional expression compared to conventional or widely used cap analogs.

      A.

      MSCap™ is designed to offer:

      • Enhanced protein expression

      • Improved functional efficacy in biological systems

      • Robust performance across multiple mRNA applications

      A.

      MSCap™ is applicable to a broad range of mRNA modalities, including:

      • Therapeutic mRNA

      • Cancer immunotherapy

      • Protein replacement and biologics

      A.

      ELONOVA focuses on technology development and therapeutic innovation. GMP manufacturing is conducted through established CDMO partners when required.

      A.

      For collaboration, licensing, or general inquiries:

      A.

      Yes. MSCap™ is available for licensing, co-development, and strategic partnerships, depending on application scope and collaboration structure.

      A.

      Yes. MSCap™ is designed to be compatible with standard in vitro transcription (IVT) workflows and can be integrated into existing mRNA production pipelines.

      A.

      Yes. ELONOVA actively engages in collaborations with pharmaceutical companies, biotech firms, CDMOs, and academic institutions through co-development and licensing models.

      A.

      Our core expertise lies in mRNA chemical engineering, including proprietary capping technologies and RNA modifications that improve translation efficiency and functional performance.